Evidence map›Paper›PMID 42182104›Full record

ArticlebioRxiv : the preprint server for biology2026

Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability.

Li He, Yuan-Wei Norman, Fushun Zhang, Ibrahim M Moustafa, David W Gohara, Chengjin Ye, Luis Martinez-Sobrido, Jamie J Arnold, Craig E Cameron, Yan Xiang

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Li HeDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
Yuan-Wei NormanDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
Fushun ZhangDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
Ibrahim M MoustafaThe Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
David W GoharaResearch Computing Consultants, LLC, Sanford, FL 32773, USA.
Chengjin YeTexas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0002-1934-9494
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0001-7084-0804
Jamie J ArnoldDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
Craig E CameronDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.ORCID 0000-0002-7564-5642
Yan XiangDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.ORCID 0000-0002-7633-1629

Funding

Translation Accelerator CoreU19AI171421 · NIAID · STANFORD UNIVERSITY · PI JEFFREY S GLENN · 2022 to 2026
$93.4M
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Coronavirus Genome ReplicationR01AI161841 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jamie Jon Arnold, CRAIG E. CAMERON · 2021 to 2026
$3.4M
High Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
$600k
NCI NIH HHS P30 CA054174NIAID NIH HHS R01 AI161841NIAID NIH HHS U19 AI171421NIH HHS S10 OD021805
6 · The paper itself

Abstract

Coronaviruses (CoVs) replicate unusually large RNA genomes that necessitate proofreading by the 3'-to-5' exoribonuclease (ExoN) formed by nonstructural proteins 14 (nsp14) and 10 (nsp10). Previous studies suggested that inactivation of the ExoN catalytic site in severe acute respiratory syndrome CoV 2 (SARS-CoV-2) is lethal, leaving unresolved whether the virus can tolerate impaired proofreading activity. Here, we investigated the functional requirement for ExoN in SARS-CoV-2 replication by combining a continuous fluorescence-based biochemical assay with an optimized single-bacmid reverse genetics system. Mutational analysis of residues involved in RNA binding or catalysis revealed graded effects on ExoN activity in vitro. Alanine substitution of Lys9, a residue positioned near the RNA-binding interface, did not reduce ExoN activity, whereas charge reversal at this position (K9E) impaired activity more strongly than alanine substitutions of the catalytic motif I residues D90 and E92 (D90A/E92A). Correspondingly, recombinant SARS-CoV-2 carrying K9A was readily recovered, whereas the D90A/E92A mutant was recovered only after an extended delay and K9E could not be rescued despite repeated attempts. The D90A/E92A mutant exhibited reduced replication while maintaining the engineered ExoN substitutions during serial passage. Deep sequencing of viral populations revealed a marked increase in genome-wide sequence variation in the D90A/E92A mutant, demonstrating a stable mutator phenotype. Together, these findings indicate that SARS-CoV-2 can tolerate substantial impairment of ExoN activity but depends on a minimal activity threshold for viability. This system provides a platform for defining how SARS-CoV-2 proofreading controls genome stability, viral fitness, and sensitivity to antiviral strategies that exploit reduced replication fidelity.

Indexed as

coronavirus nsp14ExoNgenome stabilitymutator phenotypeproofreadingreplication fidelityreverse geneticsSARS-CoV-2

Identifiers

PMID42182104
PMCPMC13192623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.